Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy

Area of Science:

• Endocrinology
• Metabolic Disorders
• Diagnostic Assays

Background:

• Metreleptin improves metabolic parameters in generalized lipodystrophy (GLD) but has variable effects in partial lipodystrophy (PLD).
• Accurate measurement of leptin levels is crucial for predicting treatment response to metreleptin.

Purpose of the Study:

• To compare three different leptin assays: Millipore radioimmunoassay (RIA), Millipore enzyme-linked immunosorbent assay (MELISA), and R&D Systems enzyme-linked immunosorbent assay (RDELISA).
• To evaluate the diagnostic performance of these assays in identifying patients who will respond to metreleptin therapy.

Main Methods:

• Cross-sectional analysis of assay bias for Study I.
• Retrospective analysis of diagnostic accuracy using receiver operating characteristic (ROC) curves for Study II.
• Leptin concentrations measured using RIA, MELISA, and RDELISA.
• Treatment response defined by reduction in HbA1c or triglycerides.

Main Results:

• The three leptin assays (RIA, MELISA, RDELISA) demonstrated significant bias and are not interchangeable.
• All assays modestly predicted metreleptin response in combined GLD and PLD cohorts (ROC AUC 0.69–0.74).
• Predictive power was lower in the PLD subgroup (ROC AUC 0.61–0.65), with no significant findings.
• A reproducible cut point for metreleptin response was not identified across assays.

Conclusions:

• The investigated leptin assays are not interchangeable, posing challenges for consistent clinical interpretation.
• A reliable diagnostic cut point to predict metreleptin responders could not be established using these assays.
• Further research is needed to develop standardized and reliable leptin assays for guiding lipodystrophy treatment.